Osimertinib as a Potential Targeted Therapy for Non-Small Cell Lung Carcinoma (NSCLC) Patients with EGFR Exon 20 T790M

BACKGROUND: Emergence of drug resistance due to epidermal growth factor receptor (EGFR) Exon 20 T790M poses a challenge in the effective management of non-small cell lung carcinoma (NSCLC). Significant breakthrough in the management of NSCLC with a specific genetic alteration causes substantial cond...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Indonesian Biomedical Journal
المؤلفون الرئيسيون:	Nur Zam Zam, Harun Iskandar, Nur Ahmad Tabri, Arif Santoso, Nurjannah Lihawa, Harry Akza Putrawan, Ferry Sandra
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Secretariat of The Indonesian Biomedical Journal 2023-10-01
الوصول للمادة أونلاين:	https://inabj.org/index.php/ibj/article/view/2431

مواد مشابهة

Vascular endothelial growth factor (VEGF) as a diagnostic marker of non-small cell lung cancer
حسب: Noor Mey Wardhani, وآخرون
منشور في: (2025-05-01)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
حسب: Michael Cekay, وآخرون
منشور في: (2023-08-01)

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
حسب: Ou Yamaguchi, وآخرون
منشور في: (2023-11-01)

Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC
حسب: Meiyi XU, وآخرون
منشور في: (2023-02-01)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
حسب: Hanping Wang, وآخرون
منشور في: (2020-03-01)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
حسب: Xiaoying Zhang
منشور في: (2021-06-01)

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
حسب: Asim Joshi, وآخرون
منشور في: (2022-08-01)

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors
حسب: Ikei S. Kobayashi, MD, PhD, وآخرون
منشور في: (2024-01-01)

Efficacy of osimertinib in advanced T790M-positive NSCLC after progression to prior EGFR-TKI: real world data from a Brazilian cohort
حسب: Luiz Henrique Araujo, وآخرون
منشور في: (2020-01-01)

Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation
حسب: David Barthélémy, وآخرون
منشور في: (2025-05-01)

Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis
حسب: Xinyue Wang, وآخرون
منشور في: (2025-04-01)

Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity
حسب: Xiuning Le, وآخرون
منشور في: (2025-09-01)

Osimertinib-Induced Hepatitis Following Immunotherapy in a Patient with Lung Adenocarcinoma Harboring De Novo EGFR Exon 19 Deletion and T790M Mutations: A Case Report
حسب: Bradley Steiner, وآخرون
منشور في: (2025-06-01)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
حسب: Sai-Hong Ignatius Ou, MD, وآخرون
منشور في: (2023-10-01)

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
حسب: Bin-Chi Liao, MD, وآخرون
منشور في: (2021-01-01)

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
حسب: Vincent D. de Jager, وآخرون
منشور في: (2024-05-01)

Osimertinib for an Advanced NSCLC Patient with Two Common EGFR Mutations and a Concomitant MET Exon 14 Skipping Mutation: A Case Report
حسب: Liu Z, وآخرون
منشور في: (2023-07-01)

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
حسب: Tia Cheunkarndee, BA, وآخرون
منشور في: (2024-06-01)

Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
حسب: Y. Uehara, وآخرون
منشور في: (2024-09-01)

The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis
حسب: Liuxian Guo, وآخرون
منشور في: (2024-04-01)

A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib
حسب: Umberto Malapelle, وآخرون
منشور في: (2022-09-01)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
حسب: Jingran Ji, MD, وآخرون
منشور في: (2023-03-01)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
حسب: Marcin Skrzypski, وآخرون
منشور في: (2017-09-01)

Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR‐mutated NSCLC
حسب: Yusuke Hamakawa, وآخرون
منشور في: (2023-09-01)

Editorial - T790M mutation and clinical outcomes with genuine osimertinib
حسب: Purvish M Parikh
منشور في: (2019-01-01)

Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M‐positive non‐small cell lung cancer
حسب: Hye Sook Kim, وآخرون
منشور في: (2023-06-01)

Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review
حسب: Chihiro Maeda, وآخرون
منشور في: (2023-10-01)

Efficacy of Osimertinib Combined with Bevacizumab in Advanced Non-small Cell  Lung Cancer Patients with Acquired EGFR T790M Mutation
حسب: Yanfei GU, وآخرون
منشور في: (2022-12-01)

Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis
حسب: Guojin Zhou, وآخرون
منشور في: (2024-01-01)

Droplet Digital PCR as a Molecular Tool for the Detection of the EGFR T790M Mutation in NSCLC Patients with the EGFR Activating Mutations
حسب: Durgut S, وآخرون
منشور في: (2024-03-01)

Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
حسب: Jiameng Lu, وآخرون
منشور في: (2024-01-01)

Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC
حسب: Elizabeth Marrett, وآخرون
منشور في: (2024-07-01)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
حسب: A.J. Piper-Vallillo, MD, وآخرون
منشور في: (2022-06-01)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
حسب: Fionnuala Crowley, MB BCh BAO, وآخرون
منشور في: (2022-01-01)

The relationship between vitamin D levels and clinical symptoms and lesion size in chest radiographs of pulmonary tuberculosis in patients with comorbid diabetes mellitus
حسب: Andi Nurrahma Ramli, وآخرون
منشور في: (2025-09-01)

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
حسب: Yosuke Miyashita, وآخرون
منشور في: (2021-02-01)

Cost-effectiveness analysis of amivantamab plus chemotherapy versus chemotherapy alone in NSCLC with EGFR Exon 20 insertions
حسب: Ping Yue, وآخرون
منشور في: (2024-03-01)

Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports
حسب: Guangrui Li, وآخرون
منشور في: (2023-10-01)

Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC
حسب: Pi-Hung Tung, وآخرون
منشور في: (2024-01-01)

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC.
حسب: Michael E Goldberg, وآخرون
منشور في: (2018-01-01)